Nikkei: IPOX® Founder Josef Schuster Comments on SpaceX’s Nasdaq Debut and Future IPO Market Signals

IPOX® CEO & Founder Josef Schuster

Nikkei, Japan’s largest business newspaper, reported on SpaceX’s listing on the Nasdaq market, examining the valuation, post-listing share price outlook, and potential implications for other major IPOs expected in the U.S. market.

IPOX® Founder Josef Schuster was featured in the article, providing analysis on SpaceX’s market reception and the broader signal the listing may send to future large IPO candidates. Schuster noted that SpaceX’s post-listing performance reflected strong investor demand and demonstrated the ability of U.S. capital markets to absorb very large offerings.

Schuster also discussed factors influencing SpaceX’s valuation, including investor expectations tied to Elon Musk, the company’s Starlink and AI-related developments, and the likelihood that fundamentals will become increasingly important after several earnings reports. He cautioned that downside risk could emerge if earnings miss targets or guidance is revised lower, while emphasizing that SpaceX’s core competitive advantage remains in its space business.

“SpaceX’s post-listing share price movement clearly reflected strong demand. It also demonstrated the strength of U.S. capital markets in absorbing such a large deal, sending a very positive message to other large IPOs expected in the future.”

“Over the short term, in the next three to six months, the share price will likely be driven by news.”

“However, if earnings fail to meet targets or guidance is revised downward, downside risk could emerge for the share price.”

The article also included commentary from University of Florida Professor Emeritus Jay Ritter, who cautioned that large IPOs with high price-to-sales ratios have historically faced weaker share performance after listing, questioning whether SpaceX’s valuation could be justified.

Read the full article by Riko Sato and Kaori Yoshida on Nikkei: スペースX、上場後の株価に「下振れリスク」 米識者に聞く

Previous
Previous

SchusterWatch #846 (6/15/2026)

Next
Next

Reuters: IPOX® Associate Lukas Muehlbauer Comments on Kardigan’s IPO and Biotech Market Recovery